CONFERENCE PROGRAM

Thursday, May 12, 2016

6:00 p.m.-7:30 p.m. Opening Plenary Session

Coquina North

Welcome from the chairpersons

Manuel Hidalgo, Beth Israel Deaconess Medical Center, Boston, MA

Opening remarks from the lead supporters

Julie M. Fleshman, Pancreatic Cancer Action Network

Kerri Kaplan, Lustgarten Foundation

Perspective from a patient

Anne Glauber

Opening keynote address: Title to be announced

Chairperson: Christine A. lacobuzio-Donahue, Memorial Sloan Kettering Cancer

Center, New York, NY

Andrew V. Biankin, University of Glasgow, Glasgow, Scotland

7:30 p.m.-9:00 p.m. Opening Reception

Coquina South

Friday, May 13, 2016

7:30 a.m.-8:30 a.m. Breakfast and Roundtable Discussions

Valencia Terrace

8:30 a.m.-10:15 a.m. Plenary Session 1: Epidemiology and Risk Factors

Coquina North

Chairperson: Manuel Hidalgo, Beth Israel Deaconess Medical Center,

Boston, MA

Identification of familial pancreatic cancer susceptibility genes **Nicholas J. Roberts,** Johns Hopkins University, Baltimore, MD

Genetic and non-genetic risk factors of pancreatic cancer

Gloria M. Petersen, Mayo Clinic College of Medicine, Rochester, MN

Pancreatic cancer etiology: Digging into the unknown

Núria Malats, Spanish National Cancer Center (CNIO), Madrid, Spain

Patients with severe chronic pancreatitis contain widespread and numerous pancreatic cancer-related somatic variants as detected by picodroplet-enabled

targeted sequencing

Robert W. Cowan, University of Michigan, Ann Arbor, MI

10:15 a.m.-10:45 a.m. Break

Coquina South

10:45 a.m.-12:15 p.m. Plenary Session 2: Early Detection

Coquina North

Chairperson: Kimberly A. Kelly, University of Virginia, Charlottesville, VA

Title to be announced

Raghu Kalluri, The University of Texas MD Anderson Cancer Center, Houston, TX

Serum contains enough information for early detection of pancreatic cancer

Carl Borrebaeck, Lund University, Lund, Sweden

Stroma: The key to earlier detection?

Kimberly A. Kelly, University of Virginia, Charlottesville, VA

12:15 p.m.-2:45 p.m. Lunch (on own)

2:45 p.m.-4:30 p.m. Plenary Session 3: Innovations and New Directions in Pancreatic Cancer Therapy

Coquina North

Chairperson: Channing J. Der, UNC Lineberger Comprehensive Cancer Center,

Chapel Hill, NC

Drugging undruggable KRAS: Will MYC do the trick?

Channing J. Der, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC

Role of stereotactic body radiation therapy in patients with locally advanced and

borderline resectable pancreas cancer

Joseph M. Herman, Johns Hopkins University, Baltimore, MD

Tumor metabolism and early metabolic response predicts survival of metastatic

pancreatic cancer patients treated with FOLFIRINOX chemotherapy

Do-Youn Oh, Seoul National University Hospital, Seoul, Republic of Korea

Mutant p53 promotes adenocarcinoma in pancreatic ductal cells

Jennifer M. Bailey, The University of Texas Health Science Center, Houston, TX

Nrf2 promotes mRNA translation in pancreatic cancer

lok In Christine Chio, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

4:30 p.m.-5:00 p.m. Break

Coquina South

5:00 p.m.-6:00 p.m. Keynote Address

Coquina North

Chairperson: Robert H. Vonderheide, Abramson Cancer Center, University of

Pennsylvania, Philadelphia, PA

Biomarker selected therapy for pancreas ductal adenocarcinoma:

An emerging reality?

Eileen M. O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY

6:00 p.m.-9:00 p.m. Poster Session A and Reception

Coquina South

Saturday, May 14, 2016

7:30 a.m.-8:30 a.m. Breakfast and Roundtable Discussions

Valencia Terrace

8:30 a.m.-10:30 a.m. Plenary Session 4: Preclinical Drug Development for Pancreatic Cancer

Coquina North

Chairperson: David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor,

NY

Pancreatic cancer biology and medicine

David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

Applications of PDX models in preclinical PDAC drug development **Manuel Hidalgo,** Beth Israel Deaconess Medical Center, Boston, MA

Stromal regulation and therapeutic targeting of the pancreatic cancer epigenome

Mara H. Sherman, Salk Institute for Biological Studies, La Jolla, CA

Genome-scale CRISPR-Cas9 screening to identify essential genes and pathways in pancreatic cancer

Andrew J. Aguirre, Dana-Farber Cancer Institute, Boston, MA

A novel $\beta 2$ adrenergic-nerve growth factor feed forward loop promotes

pancreatic cancer

Bernhard W. Renz, University of Munich, Munich, Germany

10:30 a.m.-11:00 a.m. Break

Coquina South

11:00 a.m.-1:00 p.m. Plenary Session 5: Heterogeneity of Pancreatic Cancer

Coquina North

Chairperson: Christine A. lacobuzio-Donahue, Memorial Sloan Kettering Cancer

Center, New York, NY

Heterogeneity of pancreatic cancer genomes: New insights

Christine A. Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center, New York,

NY

Deconstructing pancreatic cancer

Jen Jen Yeh, University of North Carolina, Chapel Hill, North Carolina

Reconstructing compartment-specific regulatory programs in pancreatic cancer **Kenneth P. Olive,** Columbia University Irving Comprehensive Cancer Center,

New York, NY

The global phospho-proteome of K-Ras mutant cells and tissues **Kevin M. Haigis,** Beth Israel Deaconess Medical Center, Boston, MA

1:00 p.m.-4:00 p.m. Poster Session B and Lunch

Coquina South

4:00 p.m.-6:15 p.m.

Plenary Session 6: Molecular Drivers of Pancreatic Cancer Biology and Metastasis

Chairperson: Ben Z. Stanger, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

Probing tumor heterogeneity with mouse models

Ben Z. Stanger, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

Defining the balance between division and dissemination in pancreas cancer **Sunil R. Hingorani,** Fred Hutchinson Cancer Research Center, Seattle, WA

Biological drivers of pancreatic cancer

Dafna Bar-Sagi, New York University Langone Medical Center, New York, NY

Deconstructing p53 transcriptional networks in pancreatic cancer suppression **Laura D. Attardi,** Stanford University, Stanford, CA

Hypoxia-induced Blimp1 expression induces a transient metastatic heterogeneity in pancreatic cancer

Monte M. Winslow, Stanford University School of Medicine, Stanford, CA

Loss of SIRT6 reactivates the RNA-binding protein Lin28b to drive pancreatic cancer **Sita Kugel,** Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA

Sunday, May 15, 2016

7:30 a.m.-8:30 a.m.

Breakfast and Mentoring Roundtables

Valencia Terrace

8:30 a.m.-10:30 a.m.

Plenary Session 7: Immune Drug Development

Coquina North

Chairperson: Marina Pasca Di Magliano, University of Michigan, Ann Arbor, MI

Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immune-suppressive environment in pancreatic cancer **Marina Pasca Di Magliano,** University of Michigan, Ann Arbor, MI

Reprograming the tumor microenvironment to improve responses to immunotherapy **David G. DeNardo,** Washington University School of Medicine, St. Louis, MO

Immune landscape of human pancreatic cancer

Robert H. Vonderheide, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

CXCR2 inhibition suppresses metastasis and improves the response to immunotherapy in pancreatic cancer

Jennifer P. Morton, Cancer Research UK Beatson Institute, Glasgow, United Kingdom

Dual CCR2/CXCR2 chemokine receptor blockade prevents tumor compensatory myeloid recruitment in pancreatic cancer

Timothy M. Nywening, Washington University, St. Louis, MO

CONFERENCE PROGRAM

10:30 a.m.-11:00 a.m. Break

Coquina South

11:00 a.m.-1:00 p.m. Plenary Session 8: Big Picture/Wrap-up Panel Discussion

Coquina North

Moderator: Robert H. Vonderheide, Abramson Cancer Center, University of

Pennsylvania, Philadelphia, PA

Panelists:

Jordan D. Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN Jonathan R. Brody, Thomas Jefferson University, Philadelphia, PA Lynn Matrisian, Pancreatic Cancer Action Network, Manhattan Beach, CA

Allyson J. Ocean, Weill Cornell Medical Center, New York, NY

Q&A

1:00 p.m. Closing Remarks and Departure